---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-001407"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T09:08:19.656891+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology provides LYMPHIR launch update; commercialization planned for H1 2025

## Summary
- LYMPHIR (immunotherapy for CTCL) approved Aug 2024; launch targeted for first half of 2025.
- First-year launch supply produced under commercial supply agreements with CMOs.
- J-code application submitted under HCPCS; NCCN guidelines inclusion secured.
- Patient assistance program and specialized field sales team under development.
- Exploring international licensing partnerships and expanded indications for LYMPHIR.

## SEC filing metadata
- accession: 0001213900-25-001407
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390025001407/0001213900-25-001407-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390025001407/ea0226984-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-001407
- JSON: https://secwatch.observer/filing/0001213900-25-001407.json
- Plain text: https://secwatch.observer/filing/0001213900-25-001407.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.